Trends in Mortality Due to Myocardial Infarction, Stroke, and Pulmonary Embolism in Patients Receiving Dialysis

dc.contributor.authorOcak, Gurbey
dc.contributor.authorBoenink, Rianne
dc.contributor.authorNoordzij, Marlies
dc.contributor.authorBos, Willem Jan W.
dc.contributor.authorVikse, Bjorn E.
dc.contributor.authorCases, Aleix
dc.contributor.authorKerschbaum, Julia
dc.contributor.authorHelve, Jaakko
dc.contributor.authorNordio, Maurizio
dc.contributor.authorArici, Mustafa
dc.contributor.authorMercadal, Lucile
dc.contributor.authorWanner, Christoph
dc.contributor.authorPalsson, Runolfur
dc.contributor.authorHommel, Kristine
dc.contributor.authorDe Meester, Johan
dc.contributor.authorKostopoulou, Myrto
dc.contributor.authorSantamaria, Rafael
dc.contributor.authorRodrigo, Emilio
dc.contributor.authorRydell, Helena
dc.contributor.authorBell, Samira
dc.contributor.authorMassy, Ziad A.
dc.contributor.authorJager, Kitty J.
dc.contributor.authorKramer, Anneke
dc.contributor.departmentFaculty of Medicine
dc.date.accessioned2025-11-20T09:05:28Z
dc.date.available2025-11-20T09:05:28Z
dc.date.issued2022-04-18
dc.descriptionThe ERA Registry is funded by the European Renal Association (ERA). Dr Bos reported receiving grants from Zilveren Kruis Insurance outside the submitted work. Dr Arici reported receiving personal fees from Amgen, Astellas, Astra Zeneca, Bayer, Baxter, Boehringer Ingelheim, Menarini, Merck Sharp and Dohme, Novo Nordisk, Sandoz, and Sanofi outside the submitted work. Dr Wanner reported receiving grants from and being the president of the European Renal Association during the conduct of the study. Dr Santamaria reported receiving personal fees from AstraZeneca, Vifor Fresenius Medical Care Renal Pharma, and Boehringuer Ingelheim outside the submitted work. Dr Bell reported receiving personal fees from Astra Zeneca outside the submitted work. Dr Jager reported receiving grants from the European Renal Association during the conduct of the study and receiving personal fees from Fresenius Medical Care outside the submitted work. No other disclosures were reported. Publisher Copyright: © 2022 American Medical Association. All rights reserved.en
dc.description.abstractImportance: During the past decades, improvements in the prevention and management of myocardial infarction, stroke, and pulmonary embolism have led to a decline in cardiovascular mortality in the general population. However, it is unknown whether patients receiving dialysis have also benefited from these improvements. Objective: To assess the mortality rates for myocardial infarction, stroke, and pulmonary embolism in a large cohort of European patients receiving dialysis compared with the general population. Design, Setting, and Participants: In this cohort study, adult patients who started dialysis between 1998 and 2015 from 11 European countries providing data to the European Renal Association Registry were and followed up for 3 years. Data were analyzed from September 2020 to February 2022. Exposures: Start of dialysis. Main Outcomes and Measures: The age- and sex-standardized mortality rate ratios (SMRs) with 95% CIs were calculated by dividing the mortality rates in patients receiving dialysis by the mortality rates in the general population for 3 equal periods (1998-2003, 2004-2009, and 2010-2015). Results: In total, 220467 patients receiving dialysis were included in the study. Their median (IQR) age was 68.2 (56.5-76.4) years, and 82068 patients (37.2%) were female. During follow-up, 83912 patients died, of whom 7662 (9.1%) died because of myocardial infarction, 5030 (6.0%) died because of stroke, and 435 (0.5%) died because of pulmonary embolism. Between the periods 1998 to 2003 and 2010 to 2015, the SMR of myocardial infarction decreased from 8.1 (95% CI, 7.8-8.3) to 6.8 (95% CI, 6.5-7.1), the SMR of stroke decreased from 7.3 (95% CI, 7.0-7.6) to 5.8 (95% CI, 5.5-6.2), and the SMR of pulmonary embolism decreased from 8.7 (95% CI, 7.6-10.1) to 5.5 (95% CI, 4.5-6.6). Conclusions and Relevance: In this cohort study of patients receiving dialysis, mortality rates for myocardial infarction, stroke, and pulmonary embolism decreased more over time than in the general population.en
dc.description.versionPeer revieweden
dc.format.extent931472
dc.format.extentE227624
dc.identifier.citationOcak, G, Boenink, R, Noordzij, M, Bos, W J W, Vikse, B E, Cases, A, Kerschbaum, J, Helve, J, Nordio, M, Arici, M, Mercadal, L, Wanner, C, Palsson, R, Hommel, K, De Meester, J, Kostopoulou, M, Santamaria, R, Rodrigo, E, Rydell, H, Bell, S, Massy, Z A, Jager, K J & Kramer, A 2022, 'Trends in Mortality Due to Myocardial Infarction, Stroke, and Pulmonary Embolism in Patients Receiving Dialysis', JAMA network open, vol. 5, no. 4, pp. E227624. https://doi.org/10.1001/jamanetworkopen.2022.7624en
dc.identifier.doi10.1001/jamanetworkopen.2022.7624
dc.identifier.issn2574-3805
dc.identifier.other70334416
dc.identifier.other404e423b-3302-4b04-b600-e32804250037
dc.identifier.other85128795226
dc.identifier.other35435972
dc.identifier.otherunpaywall: 10.1001/jamanetworkopen.2022.7624
dc.identifier.urihttps://hdl.handle.net/20.500.11815/7041
dc.language.isoen
dc.relation.ispartofseriesJAMA network open; 5(4)en
dc.relation.urlhttps://www.scopus.com/pages/publications/85128795226en
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectCohort Studiesen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMyocardial Infarction/epidemiologyen
dc.subjectPulmonary Embolismen
dc.subjectRenal Dialysisen
dc.subjectStroke/epidemiologyen
dc.subjectGeneral Medicineen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.titleTrends in Mortality Due to Myocardial Infarction, Stroke, and Pulmonary Embolism in Patients Receiving Dialysisen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/articleen

Skrár

Original bundle

Niðurstöður 1 - 1 af 1
Nafn:
ocak_2022_oi_220239_1649453581.82816.pdf
Stærð:
909.64 KB
Snið:
Adobe Portable Document Format

Undirflokkur